Centiva Capital’s Surmodics SRDX Stock Holding History

Centiva Capital’s Portfolio SRDX Stock Details SRDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,884	Closed	-$214K	–	2226
2023 Q4	$214K	Buy	+5,884	New	+$193K	0.01%	1391

Other funds holding SRDX

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Centiva Capital's SRDX Position: Q1 2024 in Review

Centiva Capital sold out of Surmodics (SRDX) in Q1 2024, closing a stake of 5,884 shares — an estimated $214K sold.

Centiva Capital first reported a position in SRDX in Q4 2023 and held it in 1 quarter. The position peaked at $214K in Q4 2023. 113 funds tracked by Wall St. Rank hold SRDX as of Q1 2024.

Centiva Capital reported no remaining Surmodics position as of Q1 2024 after selling out during the quarter.
Centiva Capital sold 5,884 Surmodics shares in Q1 2024, an estimated $214K.
Centiva Capital first reported a position in Surmodics in Q4 2023 and held it in 1 quarter.
Centiva Capital's Surmodics position peaked at $214K in Q4 2023.
113 funds tracked by Wall St. Rank held Surmodics as of Q1 2024.

Based on Centiva Capital's 13F filing for Q1 2024, filed 15 May 2024.